SAMPLE REQUEST

VIEW REPORT

Market Insights
According to the latest research citings of World Health Organization
(WHO) in 2018, approximately 570,000 new cases if cervical cancer were
reported which eventually represents 6.6% of all female cancers. The
early manifestation of cervical cancer are vaginal bleeding after sexual
intercourse with excruciating pain. The 2 main types of cervical cancer
are squamous cell carcinoma and adenocarcinoma. Early diagnosis and
vaccination with Gardasil can prevent the advent of cervical cancer. In the
last decade there has been a paradigm shift in the treatment regimen from
SAMPLE REQUEST

VIEW REPORT

chemotherapy to targeted therapy. Biologics in the phase III clinical trials

such as nimotuzumab and atezolizumab will provide a positive thrust to
the cervical cancer treatment market growth.
Chemotherapy is reigning the product segment for cervical cancer
treatment market. Placitaxel, cisplatin, carboplatin, gemcitabine are given
either alone or in combination with radiation therapy for patients suffering
with advanced stage cervical cancer. The combination therapy is helpful
but causes severe adverse effects. Cervical hysterectomy is helpful in
women suffering with early stage cervical cancer. Targeted drug therapy
will be the fastest growing market on account of its excellent clinical
outcomes, dose tolerability and patient compliance.
North America presently maintains supremacy in the regional segment for
cervical cancer treatment market. According to Center for Disease
Control And Prevention (CDC), cervical cancer is the second most
common type of cancer in women after breast cancer resulting in mortality
due to lack of early screening and medical intervention. Rising public
health awareness and affordable reimbursement scenario drive the
cervical cancer treatment market growth in North America. In Europe
cervical cancer is responsible for the mortality of 70% patient actively
diagnosed with cervical cancer. Presence of key players such as
F.Hoffman La-Roche AG., Merck & Co., Inc., and GlaxoSmithkline, Plc.
etc. propel the cervical cancer treatment market growth in the European
Region. Asia Pacific will be the fastest growing market during the forecast
period owing to the presence of huge generic market and proactive
government policies to fight cervical cancer.
Biopharmaceutical companies having a strong foothold in the cervical
cancer treatment market are, Allergan, Plc., Biocon Ltd., CooperSurgical,
Inc., Eli Lilly & Company, F.Hoffman La-Roche AG, GlaxoSmithkline
Plc., Ethicon, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries
Ltd. and Varian Medical Systems, Inc.
SAMPLE REQUEST

VIEW REPORT

Key Market Movements:

 Increasing cases of women being diagnosed for cervical cancer
throughout the globe
 Rising public health awareness and affordable reimbursement
scenario for the generic drugs employed for the treatment of cervical
cancer
 Vaccination such as Gardasil is helpful in prevention of HPV
infection and strong biologics pipeline with drugs in phase III
clinical trials such as nimotuzumab and atezolizumab

ToC:
Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation
Chapter 2. Executive Summary
2.1. Global Cervical Cancer Treatment Market Portraiture
SAMPLE REQUEST

VIEW REPORT

2.2. Global Cervical Cancer Treatment Market, by Product, 2017 (US$

Mn)
2.3. Global Cervical Cancer Treatment Market, by Geography, 2017
(US$ Mn)
Chapter 3. Cervical Cancer Treatment Market: Dynamics and
Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Cervical Cancer Treatment Market,
by Key Players, 2017
Chapter 4. Global Cervical Cancer Treatment Market, by Product
4.1. Overview
4.2. Chemotherapy
4.3. Targeted Therapy
4.4. Surgical Procedure
4.5. Radiation Therapy
4.6. Others
4.7. Pipeline Analysis
4.7.1. Phase III Drugs
4.7.1.1. Z-100
4.7.1.2. ADXS11-001
4.7.1.3. Nimotuzumab
4.7.1.4. Atezolizumab
4.7.2. Tabular Representation of Drug Pipeline in Phase II and I